Join Harold Burstein, MD, PhD (Medical Oncologist) and Jennifer Bellon, MD (Radiation Oncologist) as they present their multidisciplinary expertise on a range of cases pertaining to triple negative breast cancer.
Since patients are heterogeneous, patient management should also be individualized. The cases in this webinar are designed to highlight significant clinical decision points concerning treatment selection, toxicity management, and areas of recent change or controversy in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) while reinforcing emerging data from clinical trials. This webinar will allow learners to understand how to apply the standards of care to their practice and healthcare setting.
Triple negative breast cancers (negative for hormone receptors and HER2) can be highly aggressive and marked by high rates of relapse, visceral and CNS metastases, and early death. These tumors can be resistant to chemotherapy and clinically established targeted therapies have not been identified. In the NCCN Guidelines®, systemic chemotherapy is often recommended to prevent a recurrence of disease. Selecting an appropriate therapy is a challenge.